Journal Club: <scp>Anti‐CD19</scp> Chimeric Antigen Receptor T Cell Therapy for Refractory Systemic Lupus Erythematosus

Abstract

These data suggest that CD19 CAR-T cell therapy was feasible, tolerable, and effective in this small case series of refractory SLE. Nevertheless, larger placebo-controlled trials are warranted.